Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder resulting in extremely elevated low-density lipoprotein cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular disease (ASCVD). Current guidance about its management and prognosis stems from relatively small studies, mostly from western countries. The objective of this study was to assess the clinical and genetic characteristics as well as the impact of current practice on health outcomes of HoFH patients globally. Methods: The HoFH International Clinical Collaborators (HICC) registry collected data on patients with a clinical and/or genetic diagnosis of HoFH using a retrospective cohort study design. Findings: Overall, 751 patients (52% female) from 38 countries were included, with 75% reporting bi-allelic pathogenic variants. Median age of diagnosis was 12∙0 (IQR 5∙5–27∙0) years, with major manifestations of ASCVD or aortic stenosis already present in 9% at diagnosis of HoFH. Globally, pre-treatment LDL-C levels were 14∙7 (IQR 11∙6–18∙4) mmol/L, with 92% of patients subsequently receiving statins, 64% ezetimibe and 39% lipoprotein apheresis. On-treatment LDL-C levels were lower in high-income versus non-high-income countries (3∙93 [IQR 2∙6–5∙8] versus 9∙3 [IQR 6∙7–12∙7] mmol/L), with greater use of three or more lipid-lowering therapies (LLT) (66% versus 24%) and consequently more patients attaining guideline-recommended LDL-C goals (21% versus 3% respectively). A first major adverse cardiovascular event occurred a decade earlier in non-high-income countries, at a median age of 24∙5 (IQR 17∙0–34∙5) versus 37∙0 (IQR 29∙0–49∙0) years in high-income countries (adjusted hazard ratio: 1∙64 [95%CI 1∙13–2∙38]). Interpretation: Worldwide, patients with HoFH are diagnosed too late, undertreated and at high premature ASCVD risk. Greater use of multi-LLT regimens associates with lower LDL-C levels and better outcomes. Significant global disparities exist in treatment regimens, control of LDL-C levels and cardiovascular event-free survival, which demands a critical re-evaluation of global health policy to reduce inequalities and improve outcomes for all patients with HoFH. Study registration: ClinicalTrials.gov NCT04815005 (link) Funding: Detailed at end of paper (see Acknowledgements).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Self-citationFerence, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationEvinacumab for Homozygous Familial Hypercholesterolemia
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004215 · Cited by 793
Self-citationHegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30264-5 · Cited by 204
Self-citation
Cited by
Cuchel, M., Raal, F. J., Hegele, R. A., Al-Rasadi, K., Arca, M., Averna, M., Bruckert, E., Freiberger, T., Gaudet, D., Harada-Shiba, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad197 · Cited by 359
Self-citation2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Raal, F., Durst, R., Bi, R., Talloczy, Z., Maheux, P., Lesogor, A., Kastelein, J. J. P., & on behalf of the ORION-5 Study Investigators (2024) · Circulation · doi:10.1161/circulationaha.122.063460 · Cited by 96
Self-citationZulkapli, R., Muid, S. A., Wang, S. M., & Nawawi, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065098 · Cited by 27
“The greater use of multi-LLT regimens is associated with lower LDL-C levels and better outcomes [37].”
Background
Metadata
- Authors
- Tromp, T. R., Hartgers, M. L., Hovingh, G. K., Vallejo-Vaz, A. J., Ray, K. K., Soran, H., Freiberger, T., Bertolini, S., Harada-Shiba, M., Blom, D. J., Raal, F. J., Cuchel, M., Tromp, T. R., Hartgers, M. L., Hovingh, G. K., Vallejo-Vaz, A. J., Ray, K. K., Soran, H., Freiberger, T., Bertolini, S. A., Harada-Shiba, M., Pang, J., Watts, G. F., Greber-Platzer, S., Mäser, M., Stulnig, T. M., Ebenbichler, C. F., Bin Thani, K., Cassiman, D., Descamps, O. S., Rymen, D., Witters, P., Santos, R. D., Brunham, L. R., Francis, G. A., Genest, J., Hegele, R. A., Kennedy, B. A., Ruel, I., Sherman, M. H., Jiang, L., Wang, L., Reiner, Ž., Blaha, V., Ceska, R., Dvorakova, J., Dlouhy, L., Horak, P., Soska, V., Tichy, L., Urbanek, R., Vaverkova, H., Vrablik, M., Zemek, S., Zlatohlavek, L., Emil, S., Naguib, T., Reda, A., Béliard, S., Bruckert, E., Gallo, A., Elisaf, M. S., Kolovou, G., Cohen, H., Durst, R., Dann, E. J., Elis, A., Hussein, O., Leitersdorf, E., Schurr, D., Setia, N., Verma, I. C., Alareedh, M. D., Al-Khnifsawi, M., Abdalsahib Al-Zamili, A. F., Rhadi, S. H., Shaghee, F. K., Arca, M., Averna, M., Bartuli, A., Bucci, M., Buonuomo, P. S., Calabrò, P., Calandra, S., Casula, M., Catapano, A. L., Cefalù, A. B., Cicero, A. F. G., D'Addato, S., D'Erasmo, L., Di Costanzo, A., Fasano, T., Gazzotti, M., Giammanco, A., Iannuzzo, G., Ibba, A., Negri, E. A., Pasta, A., Pavanello, C., Pisciotta, L., Rabacchi, C., Ripoli, C., Sampietro, T., Sbrana, F., Sileo, F., Suppressa, P., Tarugi, P., Trenti, C., Zenti, M. G., Hori, M., Ayesh, M. H., Azar, S. T., Bitar, F. F., Fahed, A. C., Moubarak, E. M., Nemer, G., Nawawi, H. M., Madriz, R., Mehta, R., Cupido, A. J., Defesche, J. C., Reijman, M. D., Roeters-van Lennep, J. E., Stroes, E. S. G., Wiegman, A., Zuurbier, L., Al-Waili, K., Sadiq, F., Chlebus, K., Bourbon, M., Gaspar, I. M., Lalic, K. S., Ezhov, M. V., Susekov, A. V., Groselj, U., Charng, M.-J., Khovidhunkit, W., Aktan, M., Altunkeser, B. B., Demircioglu, S., Kose, M., Gokce, C., Ilhan, O., Kayikcioglu, M., Kaynar, L. G., Kuku, I., Kurtoglu, E., Okutan, H., Ozcebe, O. I., Pekkolay, Z., Sag, S., Salcioglu, O. Z., Temizhan, A., Yenercag, M., Yilmaz, M., Yilmaz Yasar, H., Mitchenko, O., Lyons, A. R. M., Stevens, C. A. T., Brothers, J. A., Hudgins, L. C., Nguyen, C., Alieva, R., Shek, A., Do, D.-L., Kim, N.-T., Le, H.-A., Le, T.-T., Nguyen, M.-N. T., Truong, T.-H., Blom, D. J., Raal, F. J., & Cuchel, M.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 399
- Issue
- 10326
- Pages
- 719-728
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4210272691
- Cited by
- 205
- References
- 7
- FWCI
- 36.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. https://app.cochat.ai/papers/10.1016/s0140-6736(21)02001-8
- The paper
- Tromp, T. R., Hartgers, M. L., Hovingh, G. K., Vallejo-Vaz, A. J., Ray, K. K., Soran, H., Freiberger, T., Bertolini, S., Harada-Shiba, M., Blom, D. J., Raal, F. J., Cuchel, M., Tromp, T. R., Hartgers, M. L., Hovingh, G. K., Vallejo-Vaz, A. J., Ray, K. K., Soran, H., Freiberger, T., . . . Cuchel, M. (2022). Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. The Lancet. https://doi.org/10.1016/s0140-6736(21)02001-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.